Researchers Seek Pleural Effusions And Tissue to Create MCB Cell Lines

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 6
Volume 4
Issue 6

BOSTON, Mass--Under a grant from the US Army Breast Cancer Program, Harvard researchers are attempting to create medullary carcinoma of the breast (MCB) cell lines as part of their immunologic studies. There is currently only one line in the world for this infrequent tumor. "We are especially interested in pleural effusions (or ascites)--the best source to make cell lines--but will also use fresh, unfixed tumor tissue, and will pay all shipping costs," said investigator Richard Junghans, PhD, MD.

BOSTON, Mass--Under a grant from the US Army Breast Cancer Program,Harvard researchers are attempting to create medullary carcinomaof the breast (MCB) cell lines as part of their immunologic studies.There is currently only one line in the world for this infrequenttumor. "We are especially interested in pleural effusions(or ascites)--the best source to make cell lines--but will alsouse fresh, unfixed tumor tissue, and will pay all shipping costs,"said investigator Richard Junghans, PhD, MD.

Departments are asked to post the request, which remains in effectuntil January 1, 1998. Prior to thoracentesis, or, when possible,tumor excision, please call Dr. Junghans or Dr. P. Telleman at617-632-0943; fax: 617-632-0998. (The MCB cell line is from theArmed Forces Institute of Pathology, Atlas #67-1-42.)

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content